China Biologic Products Announces Approval for Setting Up a New Plasma Collection Station in Pu Bei County, Guangxi Province
June 30 2008 - 9:00AM
PR Newswire (US)
TAIAN CITY, Shandong, China, June 30 /Xinhua-PRNewswire-FirstCall/
-- China Biologic Products, Inc. (OTC:CBPO) (BULLETIN BOARD: CBPO)
("CBP," or "the Company"), one of the leading plasma-based
pharmaceutical companies in the People's Republic of China ("PRC"),
today announced that the Company received the approval from the
Guangxi Province Bureau of Health, to set up a new plasma
collection station in Pu Bei County, Guangxi Province. The new
plasma collection station will be located in the Centralized
Industry Zone of Pu Bei County and when it becomes operational, it
will replace CBP's existing Fang Cheng Plasma Collection Station
("Fang Cheng"). The Company's management decided to relocate the
Fang Cheng Plasma Collection Station to a more strategic location
to increase collection volumes. During the construction period, the
existing Fang Cheng Plasma Station will still continue with its
normal operations. With the approval of the new location, the
Company hopes to expand its coverage area to secure higher
collection volumes in the future. "Since we received approval to
relocate Fang Cheng earlier this year, we inspected several
relocation sites and settled on Pu Bei County as the best choice,"
said Mr. Chao Ming Zhao, the Company's CEO. "We are confident that
the new plasma collection station will help to greatly expand our
plasma supply once it is established." About China Biologic
Products, Inc. Through its indirect majority-owned subsidiary
Shandong Taibang Biological Products Co. Ltd., China Biologic
Products, Inc. (the "Company"), is principally engaged in the
research, development, production and manufacturing and sale of
plasma-based biopharmaceutical products to hospitals and other
health care facilities in China. The Company's human albumin
products are mainly used to increase blood volume and its
immunoglobulin products are used for the treatment and prevention
of diseases. Safe Harbor Statement This release may contain certain
"forward-looking statements" relating to the business of China
Biologic Products, Inc. and its subsidiary companies. All
statements, other than statements of historical fact included
herein are "forward-looking statements," including statements
regarding: the effect of relocating its plasma collection station,
the ability of the Company to achieve its commercial objectives;
the business strategy, plans and objectives of the Company and its
subsidiaries; and any other statements of non-historical
information. These forward-looking statements are often identified
by the use of forward-looking terminology such as "believes,"
"expects" or similar expressions, involve known and unknown risks
and uncertainties. Although the Company believes that the
expectations reflected in these forward-looking statements are
reasonable, they do involve assumptions, risks and uncertainties,
and these expectations may prove to be incorrect. Investors should
not place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. The Company's
actual results could differ materially from those anticipated in
these forward-looking statements as a result of a variety of
factors, including those discussed in the Company's periodic
reports that are filed with the Securities and Exchange Commission
and available on its website ( http://www.sec.gov/ ). All
forward-looking statements attributable to the Company or persons
acting on its behalf are expressly qualified in their entirety by
these factors. Other than as required under the securities laws,
the Company does not assume a duty to update these forward-looking
statements. For more information, please contact: Company Contact:
Mr. Y. Tristan Kuo CFO China Biologic Products, Inc. Tel: +86-538-
6202206 Email: Web: http://www.chinabiologic.com/ Investor
Relations Contact: Mr. Crocker Coulson President CCG Investor
Relations Tel: +1-646-213-1915 (NY office) Email: Web:
http://www.ccgir.com/ DATASOURCE: China Biologic Products, Inc.
CONTACT: Company Contact: Mr. Y. Tristan Kuo, CFO of China Biologic
Products, Inc., +86-538- 6202206, or , or
http://www.chinabiologic.com/; or Investor Relations Contact: Mr.
Crocker Coulson, President of CCG Investor Relations,
+1-646-213-1915 (NY office),or , or http://www.ccgir.com/ Web site:
http://www.chinabiologic.com/
Copyright